Retatrutide — Indexed Studies

Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.

Goetz IA, Kanu C, Hoover A et al.

Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in Patients with Chronic Kidney Disease.

Heerspink HJL, van Raalte DH, Bjornstad P et al.

Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.

Kanu C, Boye KS, Poon JL et al.

Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight.

Kanu C, Wu Q, Poon JL et al.

Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.

Wen Y, Lemen D, Lin Y et al.

The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.

Heerspink HJL, Lu Z, Du Y et al.

Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.

Coskun T, Wu Q, Schloot NC et al.

Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.

Guo H, Yang J, Huang J et al.

Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.

Xie Z, Zheng G, Liang Z et al.

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Sanyal AJ, Kaplan LM, Frias JP et al.

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.

Rosenstock J, Frias J, Jastreboff AM et al.

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

Jastreboff AM, Kaplan LM, Frías JP et al.

Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.

Briand F, Le Cudennec C, Grasset E et al.

Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.

Hitaka K, Sugawara T, Matsumoto M et al.

Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.

Chan ZH, Omar AS, Gill K et al.

Development of the Weight and Emotions Scale (WES).

Kanu C, Kimel M, Goetz I et al.

[Nephrology : what's new in 2025].

Nanchen G, Pruijm M, Lamine F et al.

Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders.

Cho YK, Jung CH

Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity.

Kanu C, Clucas C, Skalicky A et al.

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.

Giblin K, Kaplan LM, Somers VK et al.

Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge.

Viebahn GK, Khurana A, Freund L et al.

Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects.

Wang S, Liu Y, Yan Z et al.

Effect of Incretin-Based Therapies on Blood Pressure: A Systematic Review and Meta-Analysis.

Basile C, Merolla A, Mancusi C et al.

Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.

Windram M, Lovelock DF, Carew JM et al.

Inotropic effects of retatrutide in isolated human atrial preparations.

Neumann J, Ahlrep U, Hofmann B et al.

Contractile effects of retatrutide in isolated mouse atrial preparations.

Neumann J, Ahlrep U, Hofmann B et al.

Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.

Marathe SJ, Grey EW, Bohm MS et al.

Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP.

Cui X, Zhu Y, Zeng L et al.

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.

DiStefano MJ, Dardouri M, Moore GD et al.

The First Triple Agonist for Antiobesity: Retatrutide.

Tetelbaun L, Mullally JA, Frishman WH

The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity.

Deravi M, Piszczatoski C, Phillips B et al.

Retatrutide.

Ramsbacher N

Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.

Ma J, Hu X, Zhang W et al.

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide.

Li W, Zhou Q, Cong Z et al.

Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence.

Naeem M, Imran L, Banatwala UESS

Recent advances in peptide-based therapies for obesity and type 2 diabetes.

Bailey CJ, Flatt PR, Conlon JM

Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease.

Polyzos SA, Frühbeck G, Kiortsis DN

At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide.

Ruder K

Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?

Seetharaman R, Pandit S

Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond.

Tsilingiris D, Kokkinos A

Retatrutide: a triple incretin receptor agonist for obesity management.

Ray A

Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.

Jastreboff AM, Kaplan LM, Hartman ML

Triple-Hormone-Receptor Agonist Retatrutide for Obesity.

Elfeki MA, Alkhouri N

Triple-Hormone-Receptor Agonist Retatrutide for Obesity.

Bisson A, Fauchier G, Fauchier L

Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape?

Seetharaman R, Pandit S

Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss.

Harris E

A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena.

Bain SC, Min T

Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective.

Sidik S

The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.

Urva S, O'Farrell L, Du Y et al.

Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?

Doggrell SA